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1  | INTRODUC TION
Primatene® Mist (epinephrine HFA) is a proposed replacement for 
the previous over‐the‐counter asthma metered‐dose inhaler (MDI), 
Primatene Mist® CFC.1 The newly formulated epinephrine HFA MDI 
utilizes thymol as its antioxidant, an inactive ingredient not found in 
the previous Primatene Mist® CFC. According to the Code of Federal 
Regulations: “Thymol is an essential oil that is extracted from thyme, 
mandarine, and tangerine oils and is FDA approved when used as 
a synthetic flavoring (21 CFR 172.515), a preservative and indi‐
rect food additive of adhesives (21 CFR 175.105). The source plant 
(thyme), from which thymol is extracted, is generally recognized as 
a safe substance (GRASS) by FDA (21 CFR 182.10, 21 CFR 182.2).”2
Currently, thymol presents a wide range of functional possi‐
bilities in the pharmaceutical, food, and cosmetic industries.3 It 
has also been used as an additive in an inhalation anesthetic.4 For 
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Abstract
Thymol is generally recognized as a safe substance by the FDA and has been widely 
used in the pharmaceutical, food, and cosmetic industries. Pharmacokinetic (PK) 
studies of thymol have been previously conducted for oral administration, but there 
has been no PK study for inhalation administration or intravenous (IV) injection. This 
study aims at exploring and comparing the inhalation and IV PK profile of thymol in 
a mouse model. The inhalation PK for mouse model was corrected with fur/skin ab‐
sorption. Thirty‐two male CD‐1 mice were randomized into two study arms, Arm‐A 
for intravenous (n = 16) and Arm‐B for inhalation (n = 16). The amount of thymol 
in the mouse serum was measured for Arm‐A and for Arm‐B at the highest dose. 
Furthermore, 48 mice were utilized for fur/skin absorption of thymol. In total, 320 
mouse serum samples for thymol were analyzed by LC/MS method. After inhalation, 
the peak concentration of thymol in mouse serum was 42.3 ng/mL (Cmax) and oc‐
curred at 2 minutes (tmax). The AUC of the inhaled thymol at 0‐60 minutes (AUC0‐60) 
was 464 ng/mL/min. From 10‐60 minutes post‐dose, the PK inhalation curve ap‐
peared to be higher than that for the IV injection. This is likely attributed to the effect 
of absorption of thymol through the fur/skin of mice. After an adjustment by fur/skin 
absorption, the PK profile for net inhalation closely matched the two‐compartment 
model. In fact, the bioavailability for the net inhalation of thymol was 74% and 77% 
relative to that for IV injection per AUC0‐60min and AUC0‐infinite, respectively.
K E Y W O R D S
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centuries, thymol has been shown to have various pharmacologi‐
cal properties including antioxidant, free radical scavenging, anti‐
inflammatory, analgesic, antispasmodic, antibacterial, antifungal, 
antiseptic, and antitumor activities.3,5,6 Previous reports have 
studied the pharmacokinetics of thymol following oral administra‐
tion.5 However, a pharmacokinetic study of thymol has not been 
previously reported for inhalation administration or intravenous 
(IV) injection. This study aims at exploring the PK curve of thymol 
after inhalation and IV injection in the mouse model.
2  | MATERIAL S AND METHODS
The study was conducted in accordance with the Basic & Clinical 
Pharmacology & Toxicology policy for experimental and clinical 
studies.7
2.1 | Test animals
Outbred CD‐1 (cluster of differentiation 1) male mice with an ap‐
proximate age of 8 weeks were purchased from ENVIGO (formerly 
Harlan laboratories). At the time of testing, mice were at a weight 
range of 31‐37 g. The procedures for receipt, identification, and 
care of the animals are in accordance with the lab facility stand‐
ard operating procedures (SOPs). Prior to testing, the protocol was 
reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC). The routine diet for mice was 2016 Teklad 
Global 16% Protein Rodent Diet, purchased from ENVIGO. No di‐
etary ingredients were expected to interfere with the outcome of 
the studies.
In this study, a total of 32 male CD‐1 mice were randomized into 
two study arms, Arm‐A for intravenous (n = 16) and Arm‐B for inha‐
lation (n = 16).
2.2 | Test articles
The study article used for intravenous injection is 0.1 mg/mL thymol 
in saline solution. Pure thymol is first dissolved in ethanol to prepare 
a 5% (w/v) solution. The solution was diluted 500 times with 0.9% 
saline to prepare 0.1 mg/mL thymol in saline.
For the inhalation, 0.5% thymol in HFA MDI was used. This arti‐
cle contains the same ingredients as epinephrine HFA MDI, except 
there is no epinephrine active ingredient. In addition, the thymol 
concentration is 0.5%, which is 50 times the content in the epineph‐
rine HFA MDI formulation.
2.3 | Drug administration
2.3.1 | Intravenous (IV) injection
In Arm‐A, 0.1 mg/mL thymol in saline was directly injected as a bolus 
into the mouse's tail vein at a volume of 0.16 mL within 2‐3 seconds. 
The 16 mice were lightly anesthetized by isoflurane before injection. 
The total amount of thymol injected was equivalent to 16 mcg, or 
0.48 mg/kg considering an average mouse body weight of 33.6 g.
2.3.2 | Inhalation administration
In Arm‐B, a total of 16 mice were mounted into a specially designed 
stainless steel 21.5 L breathing tank. Fifteen sprays of the test arti‐
cle containing 0.5% thymol in HFA were delivered into the tank. In 
order to ensure consistent thymol concentration, a stirring fan in‐
stalled inside the tank was set at 400 RPM and was started before 
the first spray of the test article. Thirty seconds after the last spray 
(t = 0 min), two groups of eight mice were mounted into the inhala‐
tion chamber, allowing them to breathe from inside the chamber for 
10 minutes (Figure 1).
F I G U R E  1   Mice mounted to the tank 
during treatment of inhalation
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The total amount of thymol inhaled was calculated based on the 
(a) actual concentration of the thymol in the air in the tank, which 
was measured by a validated LC‐MS to be approximately 69.0 mcg/L, 
(b) the mouse breathing time (10 minute), and (c) the mouse breath 
volume per minute of 22.5 mL/min (based on the typical mouse 
breath frequency of 150 breath/min and mouse tidal volume of 
0.15 mL/breath).8 Therefore, the total amount of thymol inhaled in 
this single‐dose study was calculated to be 15.5 mcg or 0.47 mg/kg. 
The dose of thymol used in both arms was approximately the same. 
It is worth mentioning that a thymol concentration of 0.5% is about 
50 times the amount of thymol in the epinephrine HFA formulation.
2.4 | Fur‐skin absorption
In order to determine the absorption of thymol through fur and skin dur‐
ing the inhalation treatment, an additional experiment was performed 
to measure the absorption of thymol by fur and skin without thymol 
inhalation. The mice were placed in the same breathing tank described 
above but in a reversed position with their tails and body facing the tank 
(Figure 2). In this setting, both the fur and skin of the mice were exposed 
to thymol at the same concentration (69.0 mcg/L) and duration (10 min‐
utes). Mice were allowed to breathe fresh air outside of the tank during 
this trial to prevent thymol inhalation. It is expected that the PK data for 
mice fur/skin absorption will be very low, as most are near to or lower than 
quantitative limit (QL) of 5 ng/mL so that the data for fur/skin are highly 
fluctuating. In order to obtain evaluable data for mouse PK by fur/skin 
absorption, 24 × 2 = 48 mice were tested in the fur/skin PK investigational 
study. It should be noted that the dose for fur/skin absorption cannot be 
directly determined, and was estimated per AUC relative to inhalation.
2.5 | PK sampling
Following either injection or inhalation, mouse blood was collected 
from retro‐orbital sinus under anesthesia (isoflurane) at baseline and 
2, 5, 10, 20, 30, and 60 minutes post‐dose. Due to the small body 
weight of mice, and the limited volume of mouse blood that can be 
collected, the mice in each study arm were further divided into dif‐
ferent subgroups. Specifically, PK samples of 50% of mice (n = 8) in 
Arm‐A and Arm‐B were collected at baseline, 2, 10, and 30 minutes. 
The samples of the other 50% (n = 8) in each arm were collected at 
baseline 5, 20, and 60 minutes. The combination of PK data from 
subgroups for each arm would provide a global PK profile of thymol 
in mice. For the fur/skin absorption study, the same sampling points 
(n = 24) were conducted.
2.6 | Determination of thymol in mouse serum
A solid‐phase extraction and LC/MS method was developed and 
validated to quantify the concentration of thymol in mouse serum. 
Eugenol, a member of the phenylpropanoid class of chemical com‐
pounds, is used as an internal standard for serum samples and was 
extracted by a solid‐phase extraction technique using a Waters 
Oasis HLB 96‐well μElution plate. The extracts were then subjected 
to high‐performance liquid chromatography on a Phenomenex 
Kinetex C18 30 × 2.1 mm column and eluted by a gradient pro‐
gram of mobile phase A (0.1% Formic Acid in deionized water) and 
B (0.1% Formic Acid in methanol) with a flow rate of 0.3 mL/min. 
The chromatographic runtime was 7 min per injection. Compounds 
were determined by Thermo TQS Quantiva triple quadrupole mass 
spectrometer equipped with a heated electrospray ionization source 
in MS/MS mode.
The analytical method was validated using a Quantitative limit of 
5 ng/mL and a Linearity range of 5 to 5000 ng/mL. Six levels of cal‐
ibration standards were included in each calibration curve. The cor‐
relation coefficient was found to be 0.9933‐0.9998 and the method 
precision CV was found to be 6.8%‐9.1%. Furthermore, the method 
accuracy was 93%‐97% and the mean recovery for thymol was 96% 
and 92% for the internal standard.
F I G U R E  2   Mice positioned to breathe 
fresh air outside the tank with the fur/skin 
exposed to thymol
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2.7 | Pharmacokinetic analysis for thymol in 
mouse model
To determine the thymol present in mouse serum from intravenous 
delivery, inhalation, and fur/skin absorption, the following PK mod‐
els10 were used for PK parameter estimation:
1. IV Study: One‐compartment model with first‐order output, after 
bolus injection
where C(t) is the concentration of the drug in serum at time t, D 
is the dose of the drug administration, Vd is the apparent volume of 
distribution, and Ke is the total elimination constant.
2. A one‐compartment model with a first‐order input and a first‐
order output was used to evaluate the PK model for thymol in 
mouse serum. The model is defined by the following equation:
where C(t), D, Vd, and Ke have the same definition as given in 
Equation (1) above and Ka is the absorption constant.
3. The two‐compartment model was also used to assess the PK pro‐
file of thymol in this study.
where α and β are elimination constants for the two compart‐
ments; Ka is the absorption constant; and A, B, and C are the related 
constants for the three terms.
The evaluation using the PK model for C(t) based on the above equa‐
tions for thymol administered by IV and thymol administered by high‐
dose inhalation, as well as fur/skin absorption, were calculated as 
shown in the following section.
In this study, the following PK parameters were evaluated:
1. Cmax – the maximum value of the thymol concentration in 
mice serum;
2. AUC0‐60min – the area under the curve of thymol concentration vs 
time between zero and 60 minutes post‐treatment;
3. AUC0‐infinity – the area under the curve of thymol concentration vs 
time between zero and the infinite time post‐treatment;
4. tmax – time needed to reach Cmax;
5. Vd – the apparent volume of distribution;
6. t1/2 – half‐life for total elimination;
7. Clt – the clearance of elimination, Clt = VdKe was used.
8. Ka – absorption constant;
9. Ke – elimination constant for one‐compartment model; and
10. α and β – elimination constants for two‐compartment model.
2.8 | PK non‐linear mixed effect (NLME) analysis 
with software WinNonLin
Standard Phoenix/WinNonLin software was used to perform 
Nonlinear Mixed Effect (NLME) modeling for population PK analy‐
sis in both one‐compartment and two‐compartment models. Using 
the QRPEM (Quasi‐Random Parametric Expectation Maximization) 
Algorithm, the best model was chosen based on the lowest Akaike 
Information Criterion (AIC). Additionally, Chi‐square evaluation 
was performed to calculate the Goodness of Fit (GOF), which is 
defined below.11
where x(ti) is the serum concentration of thymol under the model 
at the time of ti; and x̄(ti) is the population average of serum concen‐
tration of thymol at the time of ti.
2.9 | Net inhalation: adjustment of inhalation PK 
data from fur/skin absorption
During the 10‐minute breathing for inhalation study, the fur/skin of 
mice was also exposed to gas phase thymol. The PK profile for “net 
inhalation” should be the PK data of “apparent inhalation” adjusted 
based on the contribution of the fur/skin absorption seen here.
where Cj
X(t) is the thymol concentration for j‐compartment 
model in treatment X at time of t. Additionally, Cfur/skin(t) is the thy‐
mol concentration for fur/skin absorption at time of t and factor 
λ	=	0	−	1,	which	will	be	determined	by	PK	modeling	analysis	based	on	
lowest GOF according to Equation (4).
3  | RESULTS
3.1 | Comparison of PK data of thymol in IV, 
inhalation, and fur/skin administration
Three hundred and twenty (320) thymol PK samples of mouse serum 
were analyzed for IV, inhalation, and fur/skin delivery routes. The 
obtained data were summarized in Table 1. Thymol PK curves of 
each delivery route are presented in Figure 3, where the error bar 
denotes “standard error.”
Overall, the PK exposure of thymol for intravenous injection was 
higher than that of the inhalation. Cmax occurred at 2 minutes in both 
IV and inhalation administration routes and was found to be 76.6 ng/
mL and 39.2 ng/mL, respectively. During the first 10 minutes, the 
IV thymol curve was higher than the inhalation curve. However, at 
10‐20 minutes after administration, the IV thymol PK curve became 
lower than that of the inhalation curve. From 20 to 60 minutes, the 
inhalation curve continued to be higher and indicated a sustained 
release pattern characterized by an almost flat curve.
(1)C(t)=
D
Vd
e−Ket
(2)C(t)=
DKa
Vd(Ke−Ka)
(e−Ka t−e−Ke t)
(3)C(t)=Ae−훼t+Be−훽t+Ce−Kat
(4)GOF=
60min∑
ti=0
[
x̄(ti)−x(ti)
x(ti)
]2
(5)CNet Inhj (t)=C
Inh
j
(t)−휆CFur/skin(t)
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3.2 | Results of the PK parameters obtained by 
model analysis
The experimental PK data using the PK models were calculated by 
NLME with WinNonLin software. The obtained PK parameters are 
provided in Table 2.
3.3 | Thymol PK profile for IV delivery
As expected, Thymol PK for IV delivery fits one‐compartment model 
with first‐order output. Due to the fact that IV delivery was admin‐
istrated as a bolus, the IV PK profile meets instantaneous input, as 
described by Equation (1), with a GOF of 1.8.
3.4 | Thymol PK profile for absorption through the 
fur and skin of mice
The PK curve for fur/skin absorption shows a type of sustained ab‐
sorption in Figure 3 where 20 minutes after administration, the thy‐
mol level in serum for fur/skin is higher than both IV and inhalation 
delivery. The PK profile for fur/skin absorption of thymol fits the 
one‐compartment model with first‐order input and first‐order out‐
put, as described in Equation (2), with a GOF of 0.7.
A small absorption constant (Ka = 0.064) found during fur/skin 
administration of the mouse model indicates the sustained charac‐
teristic of thymol on the fur/skin of mice.
3.5 | Thymol PK profile for “net inhalation” delivery
The higher PK data found in the inhalation curve from 10 to 60 min‐
utes post‐dose may be due to the contribution from thymol absorbed 
through the fur/skin during the dosing.
Thymol Mouse PK Curves are essentially for “inhalation ‐ 
λ × skin/fur” which is a combined contribution from “skin/fur only” 
and “net Inhalation.” PK NLME analysis by Phoenix/WinNonLin for 
λ = 0, 0.25, 0.50, and 0.75 were conducted. When λ = .25, GOF has 
a minimum value of 2.3. In Table 2, the PK parameters for “net in‐
halation” (λ = .25) are also provided. More information on the “net 
inhalation” PK calculation regarding λ is provided in Figure S1.
The relatively small value of λ could be a result of multiple fac‐
tors. (a) In the fur/skin absorption study (see Figure 2), the mouse tail 
is directly exposed under thymol vapor. Mouse tails are naked and 
likely to have a higher absorption with thymol. (b) Additionally, in the 
inhalation study (see Figure 1), the mouse tail is far away from the 
thymol vapor and exposed to outside fresh air. The combination of 
these two factors causes a smaller adjustment factor λ = .25.
The bioavailability for the net inhalation of thymol (after a cor‐
rection for skin absorption of thymol) was 74% and 77% relative to 
that for IV injection per AUC0‐60 min and AUC0‐infinite, respectively, as 
shown in Table 2.
3.6 | Thymol PK profile based on PK models for IV, 
net inhalation, and fur/skin delivery
Based on the obtained PK parameters, C(t) was obtained based on 
PK models for (a) IV, (b) net inhalation, and (c) fur/tail absorption. 
The C(t) obtained per the PK model and experimental data are sum‐
marized in Table S1.
The PK curves obtained by PK models are comparable with the 
experimental data obtained from the actual PK study in Figure 4. 
The figure shows that the PK models are suitable for the mouse 
thymol PK profile by IV injection, net inhalation (after a correction 
for fur/skin absorption of thymol with λ = .25), and fur/skin deliv‐
ery routes.
TA B L E  1   Experimental serum concentrations of thymol administrated by IV, inhalation, and fur/skin in mouse model
Delivery route IV Oral "Inhalation" Fur/skin absorption
Delivery method 0.16 mL of 0.1 mg/mL thymol, 
in bolus
15 Sprays of 0.5% thymol into 21.5 L 
Tank, Breathing for 10 minutes
the same as the "Inhalation", 
but breathing outside air
Dose, µg/treatment 16 15.5 10.9
Dose, mg/kg mouse 0.48 0.47 0.33
# of mice treateda 8 × 2 8 × 2 24 × 2
Thymol concentration, in ng/mL Mean ± SEb Mean ± SEb Mean ± SEb
0 minutes 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
2 minutes 76.6 ± 6.0 39.2 ± 8.6 3.4 ± 0.4
5 minutes 41.4 ± 5.3 19.2 ± 2.1 4.0 ± 0.4
10 minutes 13.6 ± 1.0 16.0 ± 3.6 5.5 ± 0.5
20 minutes 3.7 ± 1.1 6.9 ± 1.3 7.5 ± 1.2
30 minutes 2.6 ± 0.8 6.4 ± 1.5 7.3 ± 0.9
60 minutes 0.2 ± 0.1 3.9 ± 2.2 5.9 ± 0.8
aDue to limited volume of mouse blood that can be collected, the mice in each study arm was divided into two different subgroups to provide a global 
PK profile: samples from one subgroup (n = 8 for IV and inhalation, and n = 24 for fur/skin absorption) were collected at 0, 2, 10, and 30 minutes; 
another subgroup (n = 8) were collected at 0, 5, 20, and 60 minutes. 
bSE, Standard error = s∕
√
n where, s is standard deviation, n is number of mice in the treatment. 
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4  | DISCUSSION
The major purpose of this study was to obtain the PK information 
for thymol by inhalation. IV delivery was also studied to provide a 
basic PK profile, and fur/skin absorption was studied to provide a 
basis for adjustment to obtain a PK profile for “net inhalation.” IV 
delivery for the mouse model shows a one‐compartment model with 
instantaneous input and first‐order output. Fur/skin absorption for 
the mouse model shows a one‐compartment model with first‐order 
input and first‐order output. However, the inhalation study of thymol 
shows a two‐comparment model, which is consistent with the thymol 
delivery route during inhalation from lung to central circle system.
The pharmacokinetic results confirmed the systemic exposure 
from both inhalation and IV injection of thymol in mice. Based on 
F I G U R E  3   Thymol serum 
concentration curve vs time in mouse 
model by experiment
TA B L E  2   PK parameters for thymol PK studies by IV, inhalation, and fur/skin delivery
Delivery route Intravenous
Inhalation
Fur/skin
Bioavailability for 
net inhalationApparent Net, λ = 0.25
Dose, μg 16.0 15.5 15.5 10.4  
PK model applied 1‐Compartment 2‐Compartment 2‐Compartment 1‐Compartment  
Reference equations Equation (1) Equation (3) Equation (5) Equation (2)  
PK parameters
Cmax, ng/mL 78.3 53.9 42.3 8.09 54%
AUC 0‐60 min, ng/mL*min 626.7 529.7 464.3 356.9 74%
AUC 0‐infinity, ng/mL*min 626.7 575.6 484.2 459.9 77%
tmax, min 2.00 2.00 2.00 20.0  
t1/2, min 3.43 3.24 4.73 19.5  
Vd, for first compartment, mL 136.4 125.9 64.7 647.5  
for second compartment, mL ‐ 283.3 75.4 ‐  
Clt for first compartment, mL/min 27.6 26.9 9.48 23.0  
Clt for second compartment, mL/min ‐ 52.1 14.6 ‐  
Absorption constant, Ka, min
‐1 ‐ 1.79 1.61 0.064  
Elimination constant, Ke, min
‐1 0.20 0.21 0.15 0.036  
α, min−1 ‐ 0.76 0.51 ‐  
β, min−1 ‐ 0.052 0.056 ‐  
Goodness of Fit, see Equation (4) 1.8 4.8 2.3 0.7  
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NLME analysis of population PK data, the peak concentration of net 
inhaled thymol in mouse serum was approximately 42.3 ng/mL (Cmax) 
and occurred at 2 minutes (tmax) after inhalation. The AUC of inhaled 
thymol from 0‐60 minutes (AUC0‐60 min) was 464 ng/mL × min which 
was 74% relative to thymol administrated by IV (Table 2). The elimi‐
nation half‐life was approximately 3.43 and 4.73 minutes for IV and 
net inhalation routes, respectively.
Notably, the concentration used in this PK study for inhaled thy‐
mol, 0.47 mg/Kg, is about 50 times the amount of thymol used in the 
epinephrine HFA MDI formulation. By comparison, the LD50 (median 
lethal dose) for IV administration in mice is 100 mg/kg12,13 which is 
over 200 times greater than the thymol used in this PK study and 
over 10 000 times greater than the amount in epinephrine HFA MDI. 
Therefore, the observed bioavailability of inhaled thymol in this 
study was far below the toxic levels.
As demonstrated above, the higher PK curve from the inhalation 
route relative to that of the intravenous route from 10 to 60 min‐
utes is most likely attributable to the effect of absorption of thy‐
mol through the skin and fur of mice. It is also noteworthy that mice 
have a very rapid breathing rate (150 breaths/min).8 Lung scintigra‐
phy studies in humans have shown that the faster the inspiratory 
flow, the lesser the deposition of the respirable fraction of an orally 
administered therapeutic aerosol in the lower respiratory tract.14,15 
Therefore, in addition to deposition on the fur and skin of the mice 
with subsequent absorption into the circulation, most of the dose 
delivered to the mice may have been deposited in the nose and, to 
a lesser extent, in the oral cavity and nasopharynx which was then 
swallowed with slow absorption from the GI tract.
Furthermore, using the mouse PK data obtained from this study, 
the human serum thymol concentration with epinephrine HFA use 
can be estimated. The maximum recommended daily dose of epi‐
nephrine HFA is eight inhalations; and the maximum daily dose 
of thymol in humans from epinephrine HFA is 36.6 mcg/day or 
0.73 mcg/kg/day, assuming a body weight of 50 kg for consumers 
who are at least 12 years old. Therefore, the relative daily thymol 
dose in mice is approximately 644 times (470/0.73) higher than the 
maximum daily exposure to thymol in humans when epinephrine 
HFA is used. From the mouse PK data, the estimated Cmax of thymol 
F I G U R E  4   Thymol serum 
concentration curve vs time in mouse 
model: experiment vs PK models
Items
Mice, this study 
(Experimental data)
Human, primatene mist 
(Estimation)
Dose of thymol
Maximum daily dose 15 sprays of 0.5% thymol, 
breathing for 10 minutes
Maximum daily dose 8 sprays 
of primatene mist
Thymol daily dose, mcg/
kg/day
470 0.73
Relative daily dose: 
Mouse vs human
641 1
PK parameters
Cmax, ng/mL 42.3 0.07
tmax, min 2 ~2
AUC0‐60 min, ng/mL × min 464 0.7
TA B L E  3   Estimated thymol PK 
parameters in humans from epinephrine 
HFA use
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in humans when administering epinephrine HFA at the maximum 
daily dose is approximately 0.07 ng/mL (Table 3), which is nominal, 
with a possibly faster tmax (~2 minutes). Moreover, since thymol is 
rapidly eliminated from the circulation with the elimination half‐life 
of 3.9 minutes for the mouse model, chronic inhalation of epineph‐
rine HFA would not pose any safety concerns.
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